Solutions
Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.
Insights
Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.
Our Solutions
News and Events
NewYorkBio 2019 Annual Meeting
Panelist: Jeff Berkowitz
Real Endpoints
PANEL DISCUSSION I: Impact of Pricing and Policy on the Next Decade of Therapeutic Innovation
Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition
by Roger Longman
The industry has plenty of ways to define value. Thousands of academic and corporate health economists busily grind out cost-effectiveness analyses. CMS has designated five "compendia" as guides for reimbursable value, despite bizarrely opaque decision-making behind the compendias' choices.
AMCP Annual Meeting 2019 – Financial Models to Manage Drug Spend of Gene Therapy
Jane Barlow, MD, MPH, MBA
Real Endpoints
Innovative and novel financing and reimbursement strategies may be needed to support sustainable patient access to these new treatments. During this session, managed care and provider strategies for addressing gene therapy will be explored.
Recent Insights
view archive >
February 13, 2019
Examining New Payment Ideas for Curative Therapies
How can the health industry ensure that cutting-edge gene therapies and other curative treatments get to the patients that need them, without leaving payers financially exposed? Jane F. Barlow, MD, MPH, MBA, was a speaker at the FoCUS (Financing and Reimbursement of Cure in US) Project at MIT, during the session "Putting Theory into Practice" she was quoted saying the “accessibility issue lies largely with payers.” All payers are different, and “a lot has to do with how they manage risk in their population as well as the regulatory constraints."
read full insight article >
January 28, 2019
AstraZeneca strikes a ‘novel’ deal with Medicare plan to lower patient out-of-pocket costs
In a novel bid to lower medicine costs, a drug maker has agreed to adjust the discounts that a Medicare Part D plan will receive for a treatment based on how patients respond — and the deal automatically lowers out-of-pocket costs for patients, as well. “One of the major problems we have in getting drug therapy used by people who really need it is that, for those people who are on Medicare, who have to pay co-insurance or copays, there is no really good way for manufacturers to provide copay assistance, because they are not allowed to do so,” said Roger Longman.
read full insight article >National Business Director
Top 5 Pharma
Senior Director
Specialty Access Solutions, Top 5 Pharma
Director of Operations
Reimbursement and Patient Support Services, Top 20 Pharma
Chronis H. Manolis, RPh
Vice President, Pharmacy UPMC Health Plan
Jack Bailey
President , GlaxoSmithKline U.S.